GOETTINGEN, Germany & MONTREAL--(BUSINESS WIRE)--April 3, 2006--Sartorius (GER:SRT) and ProMetic (TSX:PLI-SV) announce two agreements: Collaboration for Improved Separation Systems for Plasma Proteins. Agreement to Combine Membrane and Ligand Technologies for Expanded Product Offerings. Sartorius AG and ProMetic Life Sciences Inc. announced today the signing of a collaboration agreement utilizing bioseparation systems to recover proteins from human blood plasma, between Sartorius and ProMetic’s subsidiary ProMetic BioTherapeutics, Inc. ProMetic has developed with its partners, an innovative proprietary process, the “Plasma Protein Purification System” (PPPS), to fractionate blood plasma, which it licenses out to the blood-processing industry. Within this alliance, Sartorius will be a preferred supplier and technology provider to ProMetic’s PPPS licensees for filtration equipment and consumables. In addition, Sartorius and ProMetic BioSciences Ltd have agreed to collaborate on the development of ligand-membrane composites for the isolation of the proteins from blood plasma and other sources. These affinity composites will be based on ProMetic BioSciences Ltd’s Mimetic Ligand(TM) technology and Sartorius’ membrane chromatography technology Sartobind(R).
